Long-term effects of empagliflozin in patients with chronic kidney disease

Long-term effects of empagliflozin in patients with chronic kidney disease

<p><strong>Background:</strong> In the EMPA-KIDNEY trial, empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease progression. Post-trial follow-up was designed to asses...

Bibliografski detalji
Glavni autori:	Herrington, WG, Staplin, N, Agrawal, N, Wanner, C, Green, JB, Hauske, SJ, Emberson, JR, Preiss, D, Judge, P, Zhu, D, Dayanandan, R, Arimoto, R, Mayne, KJ, Ng, SYA, Sammons, E, Hill, M, Stevens, W, Wallendszus, K, Brenner, S, Cheung, AK, Liu, Z-H, Li, J, Hooi, LS, Liu, W, Kadowaki, T, Nangaku, M, Levin, A, Cherney, DZI, Maggioni, AP, Pontremoli, R, Deo, R, Goto, S, Rossello, X, Tuttle, KR, Steubl, D, Massey, D, Brueckmann, M, Landray, MJ, Baigent, C, Haynes, R
Daljnji autori:	EMPA-KIDNEY Collaborative Group
Format:	Journal article
Jezik:	English
Izdano:	Massachusetts Medical Society 2024

Slični predmeti

Empagliflozin in patients with chronic kidney disease
od: Herrington, WG, i dr.
Izdano: (2022)

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
od: Judge, PK, i dr.
Izdano: (2024)

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
od: Mayne, KM, i dr.
Izdano: (2024)

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
od: Mayne, K, i dr.
Izdano: (2024)

Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease
od: Mayne, K, i dr.
Izdano: (2023)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
od: Staplin, N, i dr.
Izdano: (2023)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
od: Herrington, W, i dr.
Izdano: (2018)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
od: Herrington, W, i dr.
Izdano: (2022)

Evidence for the prevention and treatment of stroke in dialysis patients
od: Herrington, W, i dr.
Izdano: (2014)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
od: Storey, B, i dr.
Izdano: (2017)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
od: Zhu, P, i dr.
Izdano: (2020)

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
od: Herrington, WG, i dr.
Izdano: (2023)

Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)
od: Staplin, N, i dr.
Izdano: (2016)

Allocated but not treated: the silent 16% – Authors' reply
od: Horby, P, i dr.
Izdano: (2022)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
od: Zhu, P, i dr.
Izdano: (2020)

Determining the relationship between blood pressure, kidney function, and chronic kidney disease: insights from genetic epidemiology
od: Staplin, N, i dr.
Izdano: (2022)

Effect of fenofibrate on progression of diabetic retinopathy
od: Preiss, D, i dr.
Izdano: (2024)

Benefits of lowering cholesterol in chronic kidney disease Reply
od: Baigent, C, i dr.
Izdano: (2011)

Conventional and genetic evidence on the association between adiposity and CKD
od: Zhu, P, i dr.
Izdano: (2020)

Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY
od: Nangaku, M, i dr.
Izdano: (2024)

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)
od: Staplin, N, i dr.
Izdano: (2015)

Analyses of cancer data from three ezetimibe trials.
od: Peto, R, i dr.
Izdano: (2008)

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
od: Storey, B, i dr.
Izdano: (2018)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
od: Haynes, R, i dr.
Izdano: (2018)

Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men.
od: Emberson, JR, i dr.
Izdano: (2010)

Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).
od: Haynes, R, i dr.
Izdano: (2014)

Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP)
od: Haynes, R, i dr.
Izdano: (2014)

Smoking and adverse outcomes in patients With CKD: the Study of Heart and Renal Protection (SHARP)
od: Emberson, J, i dr.
Izdano: (2016)

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.
od: Mafham, M, i dr.
Izdano: (2017)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
od: Herrington, W, i dr.
Izdano: (2016)

Harmonization of large-scale, heterogeneous individual participant adverse event data from randomized trials of statin therapy
od: Emberson, J, i dr.
Izdano: (2022)

Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies?
od: Preiss, D, i dr.
Izdano: (2017)

Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD
od: Lamprea-Montealegre, J, i dr.
Izdano: (2019)

Impact of CKD on household income
od: Morton, R, i dr.
Izdano: (2017)

Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis.
od: Mafham, M, i dr.
Izdano: (2011)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
od: Schlackow, I, i dr.
Izdano: (2017)

The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.
od: Herrington, W, i dr.
Izdano: (2014)

Reliability of major bleeding events in UK routine data vs clinical trial adjudicated follow-up data
od: Harper, C, i dr.
Izdano: (2023)

Comparison of routinely collected data with clinical trial adjudicated direct follow-up: post-hoc analyses of serious cardiovascular events from the United Kingdom-based ASCEND randomized trial
od: Harper, C, i dr.
Izdano: (2021)

Comparison of the accuracy and completeness of records of serious vascular events in routinely collected data vs clinical trial–adjudicated direct follow-up data in the UK: secondary analysis of the ascend randomized clinical trial
od: Harper, C, i dr.
Izdano: (2021)